Drugs / Vosevi
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Vosevi | — | 2017-07-26 | europa.eu ↗ |
| Approved | US (FDA) | VOSEVI | — | 2017-07-18 | fda.gov ↗ |
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07098481 | Sep 2025 → Dec 2027 expected | hepatitis C virus infection | ANRS, Emerging Infectious Diseases | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vosevi | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07098481 ↗ |
| Route | Oral | “ACCESS+ Strategy Vosevi 400/100/100 Oral Tablet” NCT07098481 ↗ |